Management of Patients with Metastatic Bladder Cancer in the Real-World Setting from the Multidisciplinary Team: Current Opinion of the SOGUG Multidisciplinary Working Group

por González-del-Alba, Aránzazu, Conde-Moreno, Antonio José, García Vicente, Ana M., González-Peramato, Pilar, Linares-Espinós, Estefanía, Climent, Miguel Ángel
Publicado 2022

Correction to: Bone loss induced by cancer treatments in breast and prostate cancer patients

por Castañeda, Santos, Casas, Ana, González-del-Alba, Aránzazu, Martínez-Díaz-Guerra, Guillermo, Nogués, Xavier, Ojeda Thies, Cristina, Torregrosa Suau, Óscar, Rodríguez-Lescure, Álvaro
Publicado 2022

Bone loss induced by cancer treatments in breast and prostate cancer patients

por Castañeda, Santos, Casas, Ana, González-del-Alba, Aránzazu, Martínez-Díaz-Guerra, Guillermo, Nogués, Xavier, Ojeda Thies, Cristina, Torregrosa Suau, Óscar, Rodríguez-Lescure, Álvaro
Publicado 2022

Expert recommendations on the management of patients with metastatic castration-resistant prostate cancer who progress after CHAARTED or LATITUDE

por Puente, Javier, Anido, Urbano, Climent, Miguel Ángel, Gonzalez-Billalabeitia, Enrique, Lainez, Nuria, Lambea, Julio, Maroto, José Pablo, Mendez-Vidal, Maria Jose, Montesa, Álvaro, Rodriguez, Angel, Zambrana, Curro, González-del-Alba, Aránzazu
Publicado 2020

SEOM-SOGUG clinical guideline for localized muscle invasive and advanced bladder cancer (2021)

por Valderrama, Begoña P., González-del-Alba, Aránzazu, Morales-Barrera, Rafael, Peláez Fernández, Ignacio, Vázquez, Sergio, Caballero Díaz, Cristina, Domènech, Montserrat, Fernández Calvo, Ovidio, Gómez de Liaño Lista, Alfonso, Arranz Arija, José Ángel
Publicado 2022

SEOM SOGUG clinical guideline for treatment of kidney cancer (2022)

por Méndez-Vidal, María José, Lázaro Quintela, Martin, Lainez-Milagro, Nuria, Perez-Valderrama, Begoña, Suárez Rodriguez, Cristina, Arranz Arija, José Ángel, Peláez Fernández, Ignacio, Gallardo Díaz, Enrique, Lambea Sorrosal, Julio, González-del-Alba, Aránzazu
Publicado 2023

Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer:...

por Puente, Javier, González-del-Alba, Aranzazu, Sala-Gonzalez, Núria, Méndez-Vidal, María José, Pinto, Alvaro, Rodríguez, Ángel, Cuevas Sanz, José Miguel, Muñoz del Toro, Jacobo Rodrigo, Useros Rodríguez, Eduardo, García García-Porrero, Ángela, Vázquez, Sergio
Publicado 2019

Assessing the risk of cardiovascular events in patients receiving immune checkpoint inhibitors

por Torrente, María, Blanco, Mariola, Franco, Fabio, Garitaonaindia, Yago, Calvo, Virginia, Collazo-Lorduy, Ana, Gutiérrez, Lourdes, Sánchez, Juan Cristóbal, González-del-Alba, Aranzazu, Hernández, Roberto, Méndez, Miriam, Cantos, Blanca, Núñez, Beatriz, Sousa, Pedro A. C., Provencio, Mariano
Publicado 2022

Epithelial-to-Mesenchymal Transition Mediates Resistance to Maintenance Therapy with Vinflunine in Advanced Urothelial Cell Carcinoma

por Font, Albert, Ruiz de Porras, Vicenç, Valderrama, Begoña P., Ramirez, Jose Luis, Nonell, Lara, Virizuela, José Antonio, Anido, Urbano, González-del-Alba, Aránzazu, Lainez, Nuria, Llorente, Maria del Mar, Jiménez, Natalia, Mellado, Begoña, García-Donas, Jesus, Bellmunt, Joaquim
Publicado 2021

Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16)

por Gillessen, Silke, Procopio, Giuseppe, Hayoz, Stefanie, Kremer, Eloïse, Schwitter, Michael, Caffo, Orazio, Lorente, David, Pedrazzini, Augusto, Roubaud, Guilhem, Nenan, Soazig, Omlin, Aurelius, Buttigliero, Consuelo, Delgado Mingorance, Juan Ignacio, González-del-Alba, Aránzazu, Delgado, Maria Teresa, Nole, Franco, Turco, Fabio, Pereira Mestre, Ricardo, Ribi, Karin, Cathomas, Richard
Publicado 2023

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer

por Conteduca, Vincenza, Jayaram, Anuradha, Romero-Laorden, Nuria, Wetterskog, Daniel, Salvi, Samanta, Gurioli, Giorgia, Scarpi, Emanuela, Castro, Elena, Marin-Aguilera, Mercedes, Lolli, Cristian, Schepisi, Giuseppe, Maugeri, Antonio, Wingate, Anna, Farolfi, Alberto, Casadio, Valentina, Medina, Ana, Puente, Javier, Vidal, Mª José Méndez, Morales-Barrera, Rafael, Villa-Guzmán, Jose C., Hernando, Susana, Rodriguez-Vida, Alejo, González-del-Alba, Aránzazu, Mellado, Begoña, Gonzalez-Billalabeitia, Enrique, Olmos, David, Attard, Gerhardt, De Giorgi, Ugo
Publicado 2019

Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib

por Cebrián, Arancha, Gómez del Pulgar, Teresa, Méndez-Vidal, María José, Gonzálvez, María Luisa, Lainez, Nuria, Castellano, Daniel, García-Carbonero, Iciar, Esteban, Emilio, Sáez, Maria Isabel, Villatoro, Rosa, Suárez, Cristina, Carrato, Alfredo, Munárriz-Ferrándiz, Javier, Basterrechea, Laura, García-Alonso, Mirta, González-Larriba, José Luis, Perez-Valderrama, Begoña, Cruz-Jurado, Josefina, González del Alba, Aránzazu, Moreno, Fernando, Reynés, Gaspar, Rodríguez-Remírez, María, Boni, Valentina, Mahillo-Fernández, Ignacio, Martin, Yolanda, Viqueira, Andrea, García-Foncillas, Jesús
Publicado 2017

A correlative biomarker study and integrative prognostic model in chemotherapy‐naïve metastatic castration‐resistant prostate cancer treated with enzalutamide

por Fernandez‐Perez, María P., Perez‐Navarro, Enrique, Alonso‐Gordoa, Teresa, Conteduca, Vicenza, Font, Albert, Vázquez‐Estévez, Sergio, González‐del‐Alba, Aránzazu, Wetterskog, Daniel, Antonarakis, Emmanuel S., Mellado, Begona, Fernandez‐Calvo, Ovidio, Méndez‐Vidal, María J., Climent, Miguel A., Duran, Ignacio, Gallardo, Enrique, Rodriguez Sanchez, Angel, Santander, Carmen, Sáez, Maria I., Puente, Javier, Tudela, Julian, Martínez, Alberto, López‐Andreo, Maria J., Padilla, José, Lozano, Rebeca, Hervas, David, Luo, Jun, de Giorgi, Ugo, Castellano, Daniel, Attard, Gerhardt, Grande, Enrique, Gonzalez‐Billalabeitia, Enrique
Publicado 2022

Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study

por Lainez, Nuria, García-Donas, Jesús, Esteban, Emilio, Puente, Javier, Sáez, M. Isabel, Gallardo, Enrique, Pinto-Marín, Álvaro, Vázquez-Estévez, Sergio, León, Luis, García-Carbonero, Icíar, Suárez-Rodríguez, Cristina, Molins, Carmen, Climent-Duran, Miguel A., Lázaro-Quintela, Martín, González del Alba, Aranzazu, Méndez-Vidal, María José, Chirivella, Isabel, Afonso, Francisco J., López-Brea, Marta, Sala-González, Nuria, Domenech, Montserrat, Basterretxea, Laura, Santander-Lobera, Carmen, Gil-Arnáiz, Irene, Fernández, Ovidio, Caballero-Díaz, Cristina, Mellado, Begoña, Marrupe, David, García-Sánchez, José, Sánchez-Escribano, Ricardo, Fernández Parra, Eva, Villa Guzmán, José C., Martínez-Ortega, Esther, Belén González, María, Morán, Marina, Suarez-Paniagua, Beatriz, Lecumberri, María J., Castellano, Daniel
Publicado 2016